A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
NewCo’s pipeline includes five investigational medicines
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Upgrades 2025 full-year CDMO sales and margin outlook
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Subscribe To Our Newsletter & Stay Updated